|Bid||187.50 x 800|
|Ask||188.45 x 800|
|Day's range||181.10 - 189.00|
|52-week range||74.45 - 236.17|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million. Analysts expect Ionis’s top line to rise ~30.2% to ~$135.7 million in the second quarter. The chart below shows analysts’ recommendations for Ionis stock over the last year.
BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.
Both clinical-stage biotechs have cutting-edge cancer therapies in their pipelines. But which stock wins in a head-to-head matchup?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.31. The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment ...
New treatments could be coming from Celgene and bluebird bio that reshape how we treat this life-threatening gene disorder.
Researchers successfully used an experimental gene therapy developed by biotech company Bluebird Bio Inc. to reduce the number of blood transfusions needed in people with beta-thalassemia, an inherited ...
Voyager Therapeutics (VYGR) spent $61.3 million on operating activities in 2017 compared to $42.4 million in 2016. In comparison, it generated $47.3 million from investing activities in 2016. The company’s positive investing cash flow in 2016 was attributable to proceeds from the maturities of marketable securities of $165.1 million, and it was partially offset by securities purchases of $112.4 million.
In December 2017, the FDA approved Omeros’s supplemental new drug application for expanding the use of Omidria for pediatric use. Omidria prevents intraoperative miosis and also reduces post-operative pain for individuals undergoing cataract surgery and intraocular lens replacement. In January 2018, the European Medicines Agency’s Committee for Orphan Medicinal Products responded positively to Omeros’s application for orphan drug status for OMS721 for the treatment of primary immunoglobulin A nephropathy.
On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53. On March 29, Regeneron stock closed at $344.36, which represented a ~7.2% rise from its share price in the week ended March 23, 2017. On March 21, 2018, Regeneron Pharmaceuticals announced a collaboration agreement with Alnylam Pharmaceuticals (ALNY) for the identification of RNA interference therapeutics for the treatment of chronic liver disease NASH (non-alcoholic steatohepatitis) and other related diseases.
Celgene's (CELG) stock was up by 3% after the company announced a co-promotion agreement with bluebird bio for one of its leading CAR-T candidates.
The company generated this revenue from research and development under a collaboration agreement with Novartis (NVS). In 2018, Akcea Therapeutics is expected to generate revenue of $71.3 million, while its peers Amgen (AMGN), Ionis Pharmaceuticals (IONS), and bluebird bio (BLUE) are expected to generate revenues of $22.5 billion, $582.4 million, and $23.9 million, respectively. In 2017, Akcea Therapeutics incurred research and development expenses of $126.8 million compared to $68.4 million in 2016.
Akcea Therapeutics (AKCA) is a late-stage biopharmaceutical company. AKCA’s pipeline includes volanesorsen, AKCEA-APO, AKCEA-ANGPTL, and AKCEA-APOCIII, which are based on Ionis Pharmaceuticals’ (IONS) antisense technology. In March 2018, two of the four analysts covering Akcea Therapeutics have given the stock “buy” or higher ratings, while two have given it “hold” ratings.
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
The recent volatility in the global stock market may make some investors feel queasy, but it is providing a buying opportunity in biotechnology stocks. Bhaman, whose fund received a 2018 U.S. Thomson Reuters Lipper Fund Award in the global large-cap growth fund category in New York on Tuesday, is focusing on companies such as Sage Therapeutics Inc (SAGE.O), Bluebird Bio Inc (BLUE.O) and Ionis Pharmaceuticals Inc (IONS.O) whose drugs can have multiple uses rather than pinpointing a specific ailment.
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.52. The results missed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment ...